Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 6/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | BMX | P51813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15320461 | 0.91 | EGFR (0.39) | BTKEGFRITKBMX | |
| SCHEMBL19512377 | 0.91 | EGFR (0.39) | BTKEGFRITKBMX | |
| SCHEMBL17708218 | 0.87 | EGFR (0.37) | BTKEGFRITKBMX | |
| SCHEMBL19512391 | 0.86 | AURKA (0.34) | AURKAAURKBBTKALKEGFR | |
| SCHEMBL15324374 | 0.86 | AURKA (0.34) | AURKAAURKBBTKALKEGFR | |
| SCHEMBL19527812 | 0.82 | AURKA (0.33) | AURKAAURKBBTKEGFRBMX | |
| SCHEMBL19512400 | 0.76 | EGFR (0.41) | BTKEGFRITKBMX | |
| SCHEMBL15322038 | 0.75 | EGFR (0.43) | CSNK2A2CSNK2A1AURKAAURKBBTK | |
| SCHEMBL15320608 | 0.74 | EGFR (0.46) | BTKEGFRITKBMX | |
| SCHEMBL15321086 | 0.74 | TBK1 (0.42) | CSNK2A2CSNK2A1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | CSNK2A2 158/4885CSNK2A1 163/4885AURKA 2000/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | CSNK2A2 158/4885CSNK2A1 163/4885AURKA 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.